Purixan Oral Suspension OK'd for Leukemia Regimen

Share this content:
Chemotherapy-free treatment a possibility for leukemia/lymphoma
Chemotherapy-free treatment a possibility for leukemia/lymphoma

The FDA has approved Purixan (mercaptopurine; NOVA Laboratories Limited) oral suspension for the treatment of patients with acute lymphoblastic leukemia (ALL) as part of a combination regimen.

Since the approval of mercaptopurine in 1953, it has only been available as a 50 mg tablet. For pediatric patients with ALL, the tablet formulation has not been optimal due to difficulty with body surface area dosing and adjustments. A suspension formulation allows for more accurate dosing in pediatric patients with a wide range of weights as well as more flexibility in dose adjustments.

RELATED: Hematologic Cancers Resource Center

The approval of Purixan was based on one clinical study that assessed the bioequivalence of mercaptopurine from Purinethol tablet (Teva) with that of the mercaptopurine oral suspension in a healthy adult population.

Purixan will be available as a 20 mg/mL oral suspension in 100 mL bottles.

For more information visit the NovaLabs website.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs